These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 11804691)

  • 1. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
    Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ
    Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer.
    Choi NC; Fischman AJ; Niemierko A; Ryu JS; Lynch T; Wain J; Wright C; Fidias P; Mathisen D
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1024-35. PubMed ID: 12419428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
    Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
    Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer.
    Poettgen C; Theegarten D; Eberhardt W; Levegruen S; Gauler T; Krbek T; Stamatis G; Teschler H; Kuehl H; Bockisch A; Stuschke M
    Oncology; 2007; 73(5-6):316-23. PubMed ID: 18497503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
    Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
    J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment].
    Schmücking M; Baum RP; Bonnet R; Junker K; Müller KM
    Pathologe; 2005 May; 26(3):178-89. PubMed ID: 15800765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
    Collaud S; Lardinois D; Tischler V; Steinert HC; Stahel R; Weder W
    Eur J Cardiothorac Surg; 2012 Mar; 41(3):612-6. PubMed ID: 22219415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
    Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
    Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Langen HJ; Bares R
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery.
    Arnett AL; Packard AT; Mara K; Mansfield AS; Wigle DA; Haddock MG; Park SS; Olivier KR; Garces YI; Merrell KW
    Pract Radiat Oncol; 2017; 7(6):e531-e541. PubMed ID: 28733185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
    Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma.
    Poncelet AJ; Lonneux M; Coche E; Weynand B; Noirhomme P;
    Eur J Cardiothorac Surg; 2001 Sep; 20(3):468-74; discussion 474-5. PubMed ID: 11509265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings.
    Konishi J; Yamazaki K; Tsukamoto E; Tamaki N; Onodera Y; Otake T; Morikawa T; Kinoshita I; Dosaka-Akita H; Nishimura M
    Respiration; 2003; 70(5):500-6. PubMed ID: 14665776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.
    Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Bogaert J; Maes A; Deneffe GJ; Nackaerts KL; Verschakelen JA; Lerut TE; Mortelmans LA; Demedts MG
    J Clin Oncol; 1998 Jun; 16(6):2142-9. PubMed ID: 9626214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG PET using SUV
    Huang YC; Lu HI; Huang SC; Hsu CC; Chiu NT; Wang YM; Chiu YC; Li SH
    BMC Med Imaging; 2017 Jan; 17(1):1. PubMed ID: 28056868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
    Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S
    Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
    Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and 18F-FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy: A Mono-institutional Pilot Experience.
    Genestreti G; Burgio MA; Matteucci F; Piciucchi S; Scarpi E; Monti M; Bucchi L; Parisi E; Crociani L; Gurioli C; Poletti V; Gavelli G
    Technol Cancer Res Treat; 2015 Dec; 14(6):721-7. PubMed ID: 24945370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.